Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and AustraliaAdriano Lazzarin, Miklos Salgo, Bonaventura Clotet et al.|New England Journal of Medicine|2003Cited by 653
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialJeffrey L. Lennox, Peter Sklar, Edwin DeJesus et al.|The Lancet|2009Cited by 620
Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical TrialsMark Nelson, Miklos Salgo, Keikawus Arastéh et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2005Cited by 151
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtideBonaventura Clotet, Jonathan Schapiro, François Raffi et al.|AIDS|2004Cited by 72
Plasma Viral Load Concentrations in Women and Men From Different Exposure Categories and With Known Duration of HIV InfectionGiovanni Rezza, Mauro Moroni, Antonella d’Arminio Monforte et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2000Cited by 43